Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality

A review of ticagrelor

Estella M. Davis, Jon T. Knezevich, Robyn M. Teply

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including ticagrelor, prasugrel, or clopidogrel in combination with aspirin to comprise dual antiplatelet therapy for the prevention of recurrent ischemic events. The limitations of conventional antiplatelet therapy with clopidogrel or prasugrel include the potential for low response to clopidogrel identifed through platelet reactivity or genetic testing, increased risk of bleeding with prasugrel, or slower return to normal platelet activity in patients who received either prasugrel or clopidogrel prior to emergent or planned surgical procedures. This review will discuss the pharmacokinetic and pharmacodynamic properties of ticagrelor in comparison to conventional P2Y12 receptor inhibitors and its utility in patients identifed as low responders to clopidogrel. Completed clinical studies and substudies comparing ticagrelor to clopidogrel and ongoing clinical trials evaluating ticagrelor in acute coronary syndrome patients will also be reviewed.

Original languageEnglish
Pages (from-to)67-83
Number of pages17
JournalClinical Pharmacology: Advances and Applications
Volume5
DOIs
StatePublished - Apr 18 2013

Fingerprint

clopidogrel
Cardiovascular Diseases
Technology
Morbidity
Mortality
Acute Coronary Syndrome
Blood Platelets
Platelet Aggregation Inhibitors
Genetic Testing
Percutaneous Coronary Intervention
Therapeutics
Aspirin
Ticagrelor
Pharmacokinetics
Clinical Trials
Guidelines
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality : A review of ticagrelor. / Davis, Estella M.; Knezevich, Jon T.; Teply, Robyn M.

In: Clinical Pharmacology: Advances and Applications, Vol. 5, 18.04.2013, p. 67-83.

Research output: Contribution to journalReview article

@article{2b965687982345659f0f4de22d8ecf68,
title = "Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: A review of ticagrelor",
abstract = "Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including ticagrelor, prasugrel, or clopidogrel in combination with aspirin to comprise dual antiplatelet therapy for the prevention of recurrent ischemic events. The limitations of conventional antiplatelet therapy with clopidogrel or prasugrel include the potential for low response to clopidogrel identifed through platelet reactivity or genetic testing, increased risk of bleeding with prasugrel, or slower return to normal platelet activity in patients who received either prasugrel or clopidogrel prior to emergent or planned surgical procedures. This review will discuss the pharmacokinetic and pharmacodynamic properties of ticagrelor in comparison to conventional P2Y12 receptor inhibitors and its utility in patients identifed as low responders to clopidogrel. Completed clinical studies and substudies comparing ticagrelor to clopidogrel and ongoing clinical trials evaluating ticagrelor in acute coronary syndrome patients will also be reviewed.",
author = "Davis, {Estella M.} and Knezevich, {Jon T.} and Teply, {Robyn M.}",
year = "2013",
month = "4",
day = "18",
doi = "10.2147/CPAA.S41859",
language = "English",
volume = "5",
pages = "67--83",
journal = "Clinical Pharmacology: Advances and Applications",
issn = "1179-1438",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality

T2 - A review of ticagrelor

AU - Davis, Estella M.

AU - Knezevich, Jon T.

AU - Teply, Robyn M.

PY - 2013/4/18

Y1 - 2013/4/18

N2 - Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including ticagrelor, prasugrel, or clopidogrel in combination with aspirin to comprise dual antiplatelet therapy for the prevention of recurrent ischemic events. The limitations of conventional antiplatelet therapy with clopidogrel or prasugrel include the potential for low response to clopidogrel identifed through platelet reactivity or genetic testing, increased risk of bleeding with prasugrel, or slower return to normal platelet activity in patients who received either prasugrel or clopidogrel prior to emergent or planned surgical procedures. This review will discuss the pharmacokinetic and pharmacodynamic properties of ticagrelor in comparison to conventional P2Y12 receptor inhibitors and its utility in patients identifed as low responders to clopidogrel. Completed clinical studies and substudies comparing ticagrelor to clopidogrel and ongoing clinical trials evaluating ticagrelor in acute coronary syndrome patients will also be reviewed.

AB - Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including ticagrelor, prasugrel, or clopidogrel in combination with aspirin to comprise dual antiplatelet therapy for the prevention of recurrent ischemic events. The limitations of conventional antiplatelet therapy with clopidogrel or prasugrel include the potential for low response to clopidogrel identifed through platelet reactivity or genetic testing, increased risk of bleeding with prasugrel, or slower return to normal platelet activity in patients who received either prasugrel or clopidogrel prior to emergent or planned surgical procedures. This review will discuss the pharmacokinetic and pharmacodynamic properties of ticagrelor in comparison to conventional P2Y12 receptor inhibitors and its utility in patients identifed as low responders to clopidogrel. Completed clinical studies and substudies comparing ticagrelor to clopidogrel and ongoing clinical trials evaluating ticagrelor in acute coronary syndrome patients will also be reviewed.

UR - http://www.scopus.com/inward/record.url?scp=84876998756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876998756&partnerID=8YFLogxK

U2 - 10.2147/CPAA.S41859

DO - 10.2147/CPAA.S41859

M3 - Review article

VL - 5

SP - 67

EP - 83

JO - Clinical Pharmacology: Advances and Applications

JF - Clinical Pharmacology: Advances and Applications

SN - 1179-1438

ER -